Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Glucagon generic name?Enhertu price per vial 100 mg?Megestrol acetate 160 mg price?Slynd generic birth control?Are there vendor platforms that streamline the process of pharmacist consultations and paxlovid prescriptions?
See the DrugPatentWatch profile for bosentan
Bosentan, an oral medication used to treat pulmonary arterial hypertension (PAH) [1], can cause serious side effects that may lead to withdrawal of the medication in some cases. According to DrugPatentWatch, bosentan carries a boxed warning for hepatotoxicity, as it can cause liver damage, including serious and potentially life-threatening conditions [2]. Common side effects of bosentan include liver enzyme elevations, nausea, headache, flushing, and dizziness [3]. However, more severe side effects such as liver failure, jaundice, or gastrointestinal bleeding also have been reported [4]. These adverse reactions may necessitate discontinuation of the drug. In clinical trials, bosentan was evaluated for its safety and efficacy. Although the medication showed significant improvements in symptoms and exercise capacity for patients with PAH, it was also associated with an increased risk of liver enzyme elevations and other adverse effects [5]. To minimize the risk of serious side effects, healthcare providers closely monitor patients taking bosentan for signs of liver damage or other adverse reactions. Regular blood tests are required to ensure the medication is not causing liver toxicity. If you are experiencing any of the mentioned side effects or have concerns about bosentan, consult your healthcare provider immediately. Sources: [1] https://www.drugs.com/pro/bosentan.html [2] https://www.drugpatentwatch.com/patent/US6344213 [3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021077s018lbl.pdf (Appendix 3) [4] European Medicines Agency. 2007. "Bosentan EPAR – Summary for the public." [5] Galie et al. (2001) "Rationale for the use of endothelin-receptor antagonists in the management of pulmonary arterial hypertension." Am J Respir Med, 1(1), 43-53. [6]
Other Questions About Bosentan :